a16z Podcast: The Business of Healthcare

Episode Summary

Executive Summary: This A16Z healthcare panel argues that tech-enabled, people-centered models can reduce costs while improving outcomes, especially for chronic disease like type 2 diabetes and obesity. Sean Duffy and Rajiv Singh explain why value-based care, better data, and empathy-driven workflows are creating a market for new healthcare businesses that blend automation with human support and are paid for measurable results.

Main Topics: Why healthcare needs a new operating model (Priority: 5/5): The speakers argue that U.S. healthcare spending is unsustainably high and current delivery models do not match patient needs or value creation, creating room for tech-enabled alternatives. People plus technology as the winning formula (Priority: 5/5): Both companies rely on human care teams but use software, data, and automation to scale those interactions efficiently rather than replacing people entirely. Chronic disease management as the biggest opportunity (Priority: 5/5): The discussion centers on preventable chronic conditions—especially diabetes and obesity—as areas where evidence-based interventions can be scaled with better technology and coaching. Macro tailwinds for value-based care (Priority: 4/5): Shifts toward outcomes-based reimbursement, higher deductibles, consumer engagement, and CMS/private-sector movement away from fee-for-service are making this timing favorable. Building defensible healthcare companies (Priority: 4/5): The panel emphasizes clinical proof, peer-reviewed evidence, longitudinal data, and outcomes measurement as the foundation for durable moats in healthcare. Empathy and workflow integration (Priority: 4/5): The speakers stress that healthcare transformation requires understanding incumbent stakeholders and patient context rather than trying to disrupt from the outside. Outcomes-based pricing and commercialization (Priority: 4/5): Both companies describe payment models tied to clinical success, reflecting the broader industry move toward paying for results instead of volume.

Key Arguments: Healthcare spending is rising faster than the economy and cannot continue indefinitely; better care delivery must be more efficient, not just more expensive. The best healthcare innovations will improve both quality and cost by aligning incentives with outcomes rather than volume. Human support remains essential in healthcare, but technology can automate transactional work and help care teams focus on high-value moments. Chronic disease programs can be standardized and scaled if they combine in-person or coaching elements with data-driven personalization. Value-based care, higher deductibles, and greater consumer willingness to engage digitally make this an especially favorable moment for new entrants. Healthcare companies need evidence: peer-reviewed clinical trials, pilot-vs-control studies, and measurable outcomes to win enterprise buyers and payers. Data network effects create durable advantages because every interaction improves the next intervention, unlike patent-based moats that expire. Successful transformation requires empathy for the existing healthcare system, not simplistic disruption from the outside.

Data Points: Healthcare spend as share of GDP (20–25 years ago): 10% - Rajiv Singh contrasts past healthcare spending with today’s level to show structural cost growth. Healthcare spend as share of GDP today: 19% - Used to argue the system is becoming unsustainable. Type 2 diabetes lifetime prevalence estimate: 40% of adults - Sean Duffy cites CDC estimates while discussing the scale of preventable chronic disease. U.S. healthcare spend not out of pocket: $2.7 trillion - Referenced as the enormous pool of healthcare spending that should be better aligned with value. Accolade pilot/control test size: 25,000 vs. 25,000 people - Example of controlled studies used to prove outcomes to buyers. Millions of interactions a year: Millions - Rajiv Singh describes Accolade’s scale of member interactions and measurement opportunities. Contract size example: 100,000 lives - Sean Duffy explains how Omada signs large outcomes-based contracts. Target penetration in five years: 80% of Americans - Sean Duffy states his ambition for Omada to be included in medical policy. Statin policy adoption: ~100% of Americans - Used as a benchmark for how chronic disease programs could become standard of care.

Pivotal Quotes: "The most transformative healthcare innovations of our era will all fit that rubric." — Sean Duffy: Responding to the idea that a company can both lower cost and improve quality. "It cannot be 100% of GDP." — Rajiv Singh: Arguing that healthcare spending growth must be constrained and care must be delivered more efficiently. "There’s no like disrupt from the outside shortcut." — Sean Duffy: Explaining that healthcare change requires working with existing stakeholders and understanding the system.

Implications: Healthcare startups that combine clinical evidence, human coaching, and data-driven automation can become category-defining businesses. The likely winners will be outcomes-based, deeply integrated with payers/providers, and focused on scalable chronic disease management.